The rationale for the latter approach was established in a preclinical study by Chakravarty et al., which demonstrated that thyroid cancers driven by BRAF V600E mutations in a mouse model exhibit profound suppression of sodium-iodide symporter expression, rendering them resistant to RAI. The gene discussed is BRAF; the disease is thyroid gland carcinoma.